Holen Sie sich die Stockscreener-App
0.513
31.50%
0.1229
Handel nachbörslich:
.74
0.227
+44.25%
Schlusskurs vom Vortag:
$0.3901
Offen:
$0.3991
24-Stunden-Volumen:
39.43M
Relative Volume:
28.91
Marktkapitalisierung:
$7.60M
Einnahmen:
$200.00K
Nettoeinkommen (Verlust:
$-10.95M
KGV:
-0.2599
EPS:
-1.9738
Netto-Cashflow:
$-10.78M
1W Leistung:
+36.58%
1M Leistung:
-63.09%
6M Leistung:
-65.10%
1J Leistung:
-71.66%
1-Tages-Spanne:
$0.39
$0.5442
1-Wochen-Bereich:
$0.35
$0.5442
52-Wochen-Spanne:
$0.28
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Firmenname
Soligenix Inc
Sektor
Branche
Telefon
609-538-8200
Adresse
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
0.513 | 5.78M | 200.00K | -10.95M | -10.78M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-07-28 | Herabstufung | Dawson James | Buy → Neutral |
| 2018-01-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Bestätigt | Maxim Group | Buy |
| 2017-07-17 | Eingeleitet | H.C. Wainwright | Buy |
Soligenix Inc Aktie (SNGX) Neueste Nachrichten
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo - PR Newswire
Soligenix (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates, Stock SlipsTop Trending Breakouts - Newser
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Soligenix (SNGX) Down -5.08% — Is the Sell-Off Overdone? 2026-05-21Retail Trader Picks - Newser
Soligenix (SNGX) price target decreased by 60.00% to 6.12 - MSN
Soligenix (SNGX) Crushes Q4 2025 Estimates — EPS $-0.28 Tops ViewsIntrinsic Value - Newser
TradingKey - TradingKey
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - USA Today
Soligenix | 424B3: Prospectus - Moomoo
Soligenix (SNGX) registers 1,054,688 resale shares; Q1 cash $6.03M - Stock Titan
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
HyBryte CTCL trial halted as Soligenix (SNGX) faces going concern risk - Stock Titan
Soligenix halts Phase 3 FLASH2 trial for CTCL due to futility, plans data analysis and strategic options. - Pluang
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - Lelezard
Soligenix (SNGX) Faces Setback in FLASH2 Study Results - GuruFocus
Soligenix Releases Q1 2026 Financial Results - AlphaStreet
Soligenix 1Q Loss/Shr 28c >SNGX - Moomoo
Soligenix Announces Recent Updates And First Quarter 2026 Financial Results - TradingView
Soligenix Anticipates HyBryte™ Phase 3 Results in Second Half of 2026, Reports $28.3 Million in Cash - geneonline.com
Soligenix Q1 net loss narrows on lower expenses - TradingView
SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment - MSN
A. G. P. Maintains Soligenix(SNGX.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - USA Today
Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA - RTTNews
SNGX phase 3 trial halted on HyBryte - MSN
SNGX: FLASH2 Trial Recommended to Stop for Futility - Yahoo Finance
Soligenix signals pivotal year with new drug progress - Community News
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives - TipRanks
SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment - Stocktwits
SNGX Phase 3 Trial Halted on HyBryte - Yahoo Finance
Soligenix halts lymphoma drug trial after futility analysis - Investing.com UK
Disappointment in Interim Results for Soligenix (SNGX) in Phase 3 Trial - GuruFocus
Why Is Soligenix Stock Sinking Tuesday? - Benzinga
SNGX - Finviz
Soligenix halts lymphoma drug trial after futility analysis By Investing.com - Investing.com Australia
HyBryte FLASH2 failure leaves Soligenix (NASDAQ: SNGX) facing funding and pipeline risk - Stock Titan
Soligenix Inc Announces Interim Results from Phase 3 Flash2 Trial Evaluating Hybryte in Treatment of Cutaneous T-Cell Lymphoma - marketscreener.com
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease (PR Newswire) - Aktiellt
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency (PR Newswire) - Aktiellt
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - The Globe and Mail
Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - NewMediaWire
Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status - NewMediaWire
Finanzdaten der Soligenix Inc-Aktie (SNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):